MX2011011529A - Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies. - Google Patents

Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies.

Info

Publication number
MX2011011529A
MX2011011529A MX2011011529A MX2011011529A MX2011011529A MX 2011011529 A MX2011011529 A MX 2011011529A MX 2011011529 A MX2011011529 A MX 2011011529A MX 2011011529 A MX2011011529 A MX 2011011529A MX 2011011529 A MX2011011529 A MX 2011011529A
Authority
MX
Mexico
Prior art keywords
allopurinol
treatment
skin reaction
hand foot
foot skin
Prior art date
Application number
MX2011011529A
Other languages
English (en)
Inventor
Yolanda Rodemer
Original Assignee
Advancell Advanced In Vitro Cell Technologies S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advancell Advanced In Vitro Cell Technologies S A filed Critical Advancell Advanced In Vitro Cell Technologies S A
Publication of MX2011011529A publication Critical patent/MX2011011529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de alopurinol o una sal farmacéuticamente aceptable del mismo para el tratamiento o la prevención de la reacción cutánea en manos-pies (RCMP) inducida por terapia con inhibidores multidiana de quinasa (IMQ). El alopurinol o su sal se administran de manera tópica a las zonas afectadas, palmas de las manos y plantas de los pies, preferiblemente en forma de una crema.
MX2011011529A 2009-04-29 2010-04-29 Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies. MX2011011529A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21489409P 2009-04-29 2009-04-29
EP09382058A EP2246057A1 (en) 2009-04-29 2009-04-29 Use of allopurinol for the treatment of hand foot skin reaction
PCT/EP2010/055806 WO2010125143A1 (en) 2009-04-29 2010-04-29 Use of allopurinol for the treatment of hand foot skin reaction

Publications (1)

Publication Number Publication Date
MX2011011529A true MX2011011529A (es) 2012-02-08

Family

ID=40897536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011529A MX2011011529A (es) 2009-04-29 2010-04-29 Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies.

Country Status (23)

Country Link
US (2) US8623878B2 (es)
EP (2) EP2246057A1 (es)
JP (1) JP6007101B2 (es)
KR (1) KR20120049848A (es)
CN (1) CN102421436B (es)
AR (1) AR076505A1 (es)
AU (2) AU2010243594A1 (es)
BR (1) BRPI1011971A2 (es)
CA (1) CA2759085C (es)
DK (1) DK2424538T3 (es)
ES (1) ES2434366T3 (es)
HK (1) HK1168042A1 (es)
HR (1) HRP20131070T1 (es)
IL (1) IL215831A (es)
ME (1) ME01567B (es)
MX (1) MX2011011529A (es)
NZ (1) NZ595901A (es)
PL (1) PL2424538T3 (es)
PT (1) PT2424538E (es)
RS (1) RS53005B (es)
RU (1) RU2543325C2 (es)
SI (1) SI2424538T1 (es)
WO (1) WO2010125143A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220713B2 (en) 2009-10-16 2015-12-29 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
CA2824933A1 (en) * 2011-01-18 2012-07-26 Vicus Therapeutics, Llc Pharmaceutical compositions and methods for making and using them
CN111601617A (zh) 2017-12-13 2020-08-28 上海岸阔医药科技有限公司 一种用于预防或治疗与egfr 被抑制相关疾病的方法
CN111989095A (zh) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
US20200046703A1 (en) * 2018-08-09 2020-02-13 Asymmetric Therapeutics, Llc Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278040B1 (de) * 1987-02-13 1991-08-14 Pharm-Allergan Gmbh Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) * 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
EP1609468A3 (en) * 2000-11-22 2006-01-25 Rxkinetix, Inc. A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
DK1455888T3 (da) 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
WO2003045334A2 (en) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) * 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
AU2004247108A1 (en) 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
WO2004110151A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
US20050142093A1 (en) * 2003-12-24 2005-06-30 Gregory Skover Treatment of skin with an apparatus and a benefit agent
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1791535B1 (en) 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators
EP2035006B1 (en) 2006-06-01 2010-02-17 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Also Published As

Publication number Publication date
BRPI1011971A2 (pt) 2016-04-26
AU2010243594A1 (en) 2011-11-10
JP6007101B2 (ja) 2016-10-12
EP2424538A1 (en) 2012-03-07
HK1168042A1 (en) 2012-12-21
HRP20131070T1 (hr) 2013-12-20
IL215831A0 (en) 2012-01-31
RU2543325C2 (ru) 2015-02-27
RU2011148355A (ru) 2013-06-10
AR076505A1 (es) 2011-06-15
US20100280051A1 (en) 2010-11-04
CA2759085A1 (en) 2010-11-04
RS53005B (en) 2014-04-30
CA2759085C (en) 2016-08-16
CN102421436A (zh) 2012-04-18
ME01567B (me) 2014-04-20
PT2424538E (pt) 2013-11-07
KR20120049848A (ko) 2012-05-17
EP2246057A1 (en) 2010-11-03
IL215831A (en) 2016-02-29
US20140080845A1 (en) 2014-03-20
DK2424538T3 (da) 2013-11-04
US8623878B2 (en) 2014-01-07
WO2010125143A1 (en) 2010-11-04
PL2424538T3 (pl) 2014-05-30
JP2012525358A (ja) 2012-10-22
ES2434366T3 (es) 2013-12-16
AU2016228193A1 (en) 2016-11-03
SI2424538T1 (sl) 2013-12-31
CN102421436B (zh) 2014-05-07
NZ595901A (en) 2013-11-29
EP2424538B1 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
IL195472A0 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
MY161078A (en) Topical formulation for a jak inhibitor
NZ603319A (en) Diabetes therapy
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
NZ702485A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX2011011529A (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies.
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
BR112014012054A2 (pt) métodos de tratamento com deferiprona
MX2009006574A (es) Tratamiento de cancer de pulmon.
WO2012012305A3 (en) Combination therapy using a ruthenium complex
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
JP2012525358A5 (es)
PL1732551T3 (pl) Perheksylina do leczenia przewlekłej niewydolności serca
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
WO2010095875A3 (ko) 생약을 이용한 변비치료용 패치
NZ599227A (en) Therapeutic agent for chronic pain
MX2012006217A (es) Derivados de peroxido nuevos, su proceso de preparacion y su uso en medicina humana y en cosmeticos para el tratamiento o prevencion de acne.
CY1114601T1 (el) Χρηση της αλλοπουρινολης για την αγωγη της δερματικης αντιδρασης χειρος-ποδος
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.

Legal Events

Date Code Title Description
FG Grant or registration